Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at Wedbush boosted their Q1 2025 EPS estimates for shares of Keros Therapeutics in a note issued to investors on Tuesday, December 3rd. Wedbush analyst Y. Zhong now forecasts that the company will post earnings of ($1.40) per share for the quarter, up from their previous estimate of ($1.44). Wedbush currently has a "Outperform" rating and a $84.00 price target on the stock. The consensus estimate for Keros Therapeutics' current full-year earnings is ($5.28) per share. Wedbush also issued estimates for Keros Therapeutics' Q2 2025 earnings at ($1.39) EPS, Q3 2025 earnings at ($1.37) EPS, Q4 2025 earnings at ($1.35) EPS, FY2025 earnings at ($5.51) EPS, FY2026 earnings at ($5.02) EPS, FY2027 earnings at ($4.73) EPS and FY2028 earnings at ($3.87) EPS.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $0.39 million for the quarter. During the same period in the previous year, the company earned ($1.33) earnings per share. The firm's revenue was up 4750.0% compared to the same quarter last year.
A number of other equities research analysts have also recently commented on KROS. Guggenheim restated a "buy" rating and issued a $102.00 price target (up from $96.00) on shares of Keros Therapeutics in a report on Wednesday. HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Bank of America dropped their price target on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating on the stock in a research note on Thursday, September 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Finally, Scotiabank started coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $77.00 target price on the stock. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $89.56.
Check Out Our Latest Research Report on KROS
Keros Therapeutics Stock Performance
Shares of Keros Therapeutics stock traded up $5.39 on Friday, reaching $70.00. 485,942 shares of the company's stock were exchanged, compared to its average volume of 375,712. The company has a market capitalization of $2.84 billion, a P/E ratio of -13.44 and a beta of 1.20. Keros Therapeutics has a 52 week low of $27.31 and a 52 week high of $73.00. The firm's 50-day moving average is $60.05 and its two-hundred day moving average is $52.56.
Institutional Trading of Keros Therapeutics
A number of large investors have recently added to or reduced their stakes in the stock. FMR LLC raised its holdings in shares of Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company's stock worth $284,493,000 after purchasing an additional 179,374 shares during the period. Alkeon Capital Management LLC boosted its holdings in Keros Therapeutics by 18.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after buying an additional 298,694 shares during the period. Darwin Global Management Ltd. raised its holdings in Keros Therapeutics by 6.3% during the 2nd quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company's stock valued at $68,772,000 after acquiring an additional 89,952 shares during the period. Point72 Asset Management L.P. boosted its holdings in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock worth $55,025,000 after acquiring an additional 577,220 shares during the period. Finally, Holocene Advisors LP boosted its stake in Keros Therapeutics by 22.5% in the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company's stock worth $48,959,000 after purchasing an additional 154,784 shares during the period. Hedge funds and other institutional investors own 71.56% of the company's stock.
Keros Therapeutics Company Profile
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
See Also
![Earnings History and Estimates for Keros Therapeutics (NASDAQ:KROS)](https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&Symbol=KROS)
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.